XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression

The first-in-class inhibitor of exportin-1 (XPO1) selinexor is currently under clinical investigation in combination with the BTK inhibitor ibrutinib for patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin lymphoma. Selinexor induces apoptosis of tumour cells through nuclear retention o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Jack G., Doyle, Amber D. P., Graham, Lara V., Sonar, Shreyanshi, Sale, Ben, Henderson, Isla, Del Rio, Luis, Johnson, Peter W. M., Landesman, Yosef, Cragg, Mark S., Forconi, Francesco, Walker, Christopher J., Khakoo, Salim. I., Blunt, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539165/
https://www.ncbi.nlm.nih.gov/pubmed/37528310
http://dx.doi.org/10.1038/s41375-023-01984-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539165/
https://www.ncbi.nlm.nih.gov/pubmed/37528310
http://dx.doi.org/10.1038/s41375-023-01984-z

Ejemplares similares